N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 A Study of TAK-861 in Participants With Narcolepsy Type 2
Narcolepsy Type 2
Primary: Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 — 2.14; 1.90; 4.54 minutes — p==0.989
N/A N=30 The Effects of Ashwagandha (Withania Somnifera) Supplementation on Exercise Performance in Female Footballers
Muscle Strength
Primary: Increased Lower Body Muscle Strength 1/2 — 2410.0; 2492.5 Watts
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Phase 3 N=475 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Treatment-Emergent Adverse Events — 205; 223; 14; 17 Participants
Phase 2 N=112 A Study of TAK-861 in Participants With Narcolepsy Type 1
Narcolepsy Type 1
Primary: Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 — -1.16; 12.49; 23.50; 25.42 minutes — p==0.001
N/A N=76 National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
N/A N=39 The Dietetic Consultation: an Illuminative Evaluation
Malnutrition
Primary: Experience of the Dietetic Consultation (Number of Participants With Dietetic Consultation Experience That Relate to Each Theme) — 10; 11; 13; 5 Participants
N/A N=9 Novel Helmet Design in Patients With Seizures
Drug Resistant Epilepsy · Drop Seizures · Generalized Tonic Clonic Seizure
Primary: Part 1: Number of Successful Deployments — 4; 0 number of successful deployments
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
N/A N=86 Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain
Symptomatic Neuroma · Morton's Neuroma · Chronic Nerve Pain
Primary: Change in Visual Analog Scale (VAS) For Pain Score at 12 Post-operative Months in Comparative Phase Subjects — -86.62; -72.67 Millimeters (mm) — p=0.011
Phase 1 N=27 Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
Healthy Volunteers
Primary: Part 1: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LOXO-305 — 4000; 4100 nanogram per milliliter (ng/mL)
Phase 4 N=168 A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Asthma · Severe Eosinophilic Asthma
Primary: Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period — 0.151; 0.168; 0.605 Proportion of Participants
Phase 3 N=505 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 — 28.7; 45.3; 47.8 percentage of…